UEG Week Recordings UEG Week Posters Online courses Guidelines Mistakes in... Podcasts Webinars
new
Gut Guide online
Visit ueg.eu Create myUEG account Log In
Visit ueg.eu Create myUEG account Log In

Filters:

UEG Online Course
accredited
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Functional dyspepsia: Diagnosis and treatment

Lucas Wauters, Jan Tack, Tim Vanuytsel

Summary

AI Generated

This is an online educational course on functional dyspepsia covering diagnosis using Rome IV criteria, pathophysiology, and evidence-based management approaches for the condition and its syndromes including postprandial distress and epigastric pain syndrome.

  • The course teaches diagnosis of functional dyspepsia using Rome IV criteria and recognition of cardinal and associated symptoms
  • Content covers the pathophysiology of functional dyspepsia, mechanisms of action of different drugs, and evidence-based therapy choices
  • The course includes postprandial distress syndrome and epigastric pain syndrome as recognized syndromes within functional dyspepsia
  • Combined material duration is approximately 40 minutes with an estimated 60 minutes needed to complete the course including final assessment
  • The course is suitable for gastroenterologists in training as well as physicians, surgeons, nurses, dietitians and medical students with an interest in gastroenterology
Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Overview

Functional dyspepsia is a common and chronic functional gastrointestinal disorder (FGID) defined by upper abdominal symptoms. Correct diagnosis and recognition of the existing syndromes, including postprandial distress and epigastric pain syndrome is important, as this will affect the management decisions.

All aspects of functional dyspepsia —from its definition and impact to pathophysiology and management— are covered in this online course by Lucas Wauters, Jan Tack and Tim Vanuytsel. The course includes comprehensive PPT slides and bespoke video presentations, which were filmed in Leuven in March 2020. The combined material has a total duration of approximately 40 minutes. The estimated time needed to complete the course, including the final assessment, is 60 minutes.

Learning objectives

  • How to reach a diagnosis of functional dyspepsia using Rome IV criteria
  • To recognize the cardinal and associated symptoms of functional dyspepsia
  • To understand the impact and pathophysiology of functional dyspepsia
  • To understand the mechanisms of action of different drugs used to treat functional dyspepsia
  • To make evidence-based choices on existing therapies for functional dyspepsia

Target audience

This course is suitable for gastroenterologists in training, but is also appropriate for physicians and surgeons in other disciplines, as well as nurses, dietitians and medical students who have an interest in gastroenterology.

This course was developed by Lucas Wauters, Jan Tack and Tim Vanuytsel (department of Gastroenterology and Hepatology, KU Leuven University Hospitals Leuven) in receipt of an Activity Grant from UEG.

Reviewed & updated February 2023

Event

Functional dyspepsia: Diagnosis and treatment

Topics

Neurogastroenterology & Motility

Accreditation status

accredited

Duration

1 hour

Published

2020

More Like This:

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

Kaina Chen Kaina Chen, Jason Pik Eu Chang, David Chee Eng Ng, Brian Kim Poh Goh, David Tai, Apoorva Gogna, Chow Wei Too, Yiying Pei, Melvin Joel, Reagan Ng, Michael Chu

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

Esmira Abdullayeva Esmira Abdullayeva, Rashad Hasanov, Gülüstan Babayeva

Conclusion: Mistakes in… Upper GI

Conclusion: Mistakes in… Upper GI

Manuele Furnari Manuele Furnari

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

Dalila Gargouri Dalila Gargouri, Norsaf Bibani, Houssaina Jlassi, Dorra Trad, Sabbah Meriam, Sahar Hamza

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

Antonio Scafuri Antonio Scafuri, Alessandro Federico, Marcello Dallio, paola ciamarra, Fiammetta Di Nardo, Annachiara Coppola, Rossella D'Onofrio, Marina Cipullo, Mario Romeo, Paolo Vaia

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

Marten Lantinga Marten Lantinga, Robert Bart Takkenberg, Raoel Maan, Matthijs Kramer, Frans Cuperus, Minneke J. Coenraad, Gwen M.C. Masclee, Koos de Wit

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

Michael Chu 1, Reagan Ng 2, Melvin Joel 1, Yiying Pei 1, Chow Wei Too 1, Apoorva Gogna 1, David Tai 3, Brian Kim Poh Goh 1, David Chee Eng Ng 1, Jason Pik Eu Chang 1, Kaina Chen 1

Affiliations

1 Singapore General Hospital, Singapore, Singapore

2 Lee Kong Chian School of Medicine, Singapore, Singapore

3 National Cancer Center, Singapore, Singapore

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Accurate prognostication is central to multidisciplinary tumour board (MDT) decision-making in hepatocellular carcinoma (HCC). Although the albumin–bilirubin (ALBI) grade is an established prognostic marker, its real-world performance across tumour burden, performance status (PS), and MDT-directed treatment pathways remains incompletely defined. The incremental value of tumour biology, reflected by alpha-fetoprotein (AFP), relative to conventional scores is also unclear.

Aims & Methods

We evaluated whether ALBI differentiates survival across subgroups defined by tumour burden (up-to-7; UT7), performance status (PS), and MDT-recommended treatment pathway, and if AFP adds incremental value to ALBI. We retrospectively analysed consecutive patients with new or recurrent HCC discussed at the Singapore General Hospital / National Cancer Centre Singapore weekly liver MDT (2021–2024). Of 306 cases, 289 with complete data and ≥6 months follow-up were included. Tumour burden (up-to-7; UT7), performance status (PS 0–2), and MDT-recommended treatment pathways (surgery, locoregional, systemic) were recorded. Overall survival (OS) was analysed using Kaplan–Meier and Cox regression models. Model performance was compared using likelihood ratio testing.

Results

Median age was 70 years (IQR 63–77), and 75.2% were male. Hepatitis B (38.6%) and MASLD (26.1%) were the predominant aetiologies. In the overall cohort, ALBI demonstrated clear stepwise survival separation (p<0.001), with median OS not reached for ALBI 1 (37.4%), 21.4 months (95% CI 17.8–25.9) for ALBI 2 (49.1%), and 8.6 months (95% CI 5.9–11.4) for ALBI 3 (13.5%).
ALBI remained prognostic across tumour burden strata. Within UT7, median OS was not reached, 23.1 months (95% CI 18.4–28.9), and 10.2 months (95% CI 6.7–14.6) for ALBI 1–3 (p<0.001); beyond UT7, 32.6 months (95% CI 24.1–NR), 14.7 months (95% CI 10.2–19.9), and 6.1 months (95% CI 3.8–9.4), respectively (p<0.001). Consistent stratification was observed across PS subgroups (0–2; n=276). ALBI also differentiated outcomes across MDT-recommended treatment pathways, with the greatest separation observed among locoregional therapy candidates (p<0.001).
On multivariable analysis, ALBI was a strong independent predictor of mortality (HR ≈2.8 per grade increase, p<0.001). AFP provided additional prognostic value beyond ALBI (HR ≈1.4 per log₁₀ increase, p<0.001), significantly improving model fit (p<0.001). In contrast, Child–Pugh class and composite tumour–liver scores, including up7-ALBI, did not improve prognostic performance beyond ALBI alone.

Among patients undergoing locoregional therapy, both ALBI and AFP remained independent predictors of survival. A simple 3×2 ALBI–AFP risk matrix further stratified outcomes (p<0.001), identifying a low-risk group (ALBI 1, AFP <20 ng/mL) with favourable survival and a very high-risk group (ALBI 3, AFP ≥20 ng/mL) with poor outcomes.

Conclusion

In a real-world MDT cohort, ALBI robustly stratifies survival across tumour burden, performance status, and treatment pathways, and is the dominant determinant of prognosis. AFP provides complementary information reflecting tumour biology and enhances risk discrimination. A simple ALBI–AFP framework enables clinically meaningful stratification, particularly among locoregional therapy candidates, supporting its integration into MDT-based decision-making.

Disclosure

​The authors have no conflict of interest to declare.

Event

UEG Week Barcelona 2026

Topics

Radiology & Imaging Hepatobiliary Digestive Oncology

Submission format

Abstract

Session

New directions in the management and therapy of patients with hepatocellular carcinoma

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

Kaina Chen Kaina Chen, Jason Pik Eu Chang, David Chee Eng Ng, Brian Kim Poh Goh, David Tai, Apoorva Gogna, Chow Wei Too, Yiying Pei, Melvin Joel, Reagan Ng, Michael Chu

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

Esmira Abdullayeva Esmira Abdullayeva, Rashad Hasanov, Gülüstan Babayeva

Conclusion: Mistakes in… Upper GI

Conclusion: Mistakes in… Upper GI

Manuele Furnari Manuele Furnari

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

Dalila Gargouri Dalila Gargouri, Norsaf Bibani, Houssaina Jlassi, Dorra Trad, Sabbah Meriam, Sahar Hamza

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

Antonio Scafuri Antonio Scafuri, Alessandro Federico, Marcello Dallio, paola ciamarra, Fiammetta Di Nardo, Annachiara Coppola, Rossella D'Onofrio, Marina Cipullo, Mario Romeo, Paolo Vaia

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

Marten Lantinga Marten Lantinga, Robert Bart Takkenberg, Raoel Maan, Matthijs Kramer, Frans Cuperus, Minneke J. Coenraad, Gwen M.C. Masclee, Koos de Wit

UEG Poster
New
Audio / Video Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

Gülüstan Babayeva 1, Rashad Hasanov 2,1, Esmira Abdullayeva 3

Affiliations

1 Azerbaijan State Advanced Training Institute for doctors named after A.ALIYEV, Baku, Azerbaijan

2 German Hospital Baku, Baku, Azerbaijan

3 Istanbul NS Clinic, Baku, Azerbaijan

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

The gut–liver axis has a central role in the pathophysiology of chronic liver diseases. Small intestinal bacterial overgrowth (SIBO), as a manifestation of intestinal dysbiosis, may contribute to hepatic inflammation, altered bile acid metabolism, and disease progression. However, the prevalence of SIBO across different liver disease phenotypes and its independent clinical predictors remain insufficiently defined

Aims & Methods

Aim: To determine the prevalence of SIBO in patients with liver diseases and to identify laboratory and disease-related factors independently associated with SIBO positivity.
Methods: In this cross-sectional study, consecutive patients with liver-related disorders were evaluated using a structured clinical and biochemical dataset. After data cleaning and exclusion of repeated header rows and records with unavailable SIBO status, 328 patients were included in the final analysis. Patients were stratified into SIBO-positive and SIBO-negative groups. Continuous variables were compared using non-parametric tests, while categorical variables were analyzed using chi-square testing. To identify independent predictors of SIBO, multivariable logistic regression was performed using a complete-case model including age, sex, alanine aminotransferase (ALT), alkaline phosphatase (ALP), and active/acute hepatitis C virus (HCV) status.

Results

Among 328 patients, 116 (35.4%) were SIBO-positive and 212 (64.6%) were SIBO-negative. On univariate analysis, SIBO-positive patients had significantly higher ALT [median 42.5 vs 32.0, p=0.0027], AST [33.9 vs 27.2, p=0.0115], and ALP [95.9 vs 80.8, p=0.0047] levels compared with SIBO-negative patients. No significant differences were observed for sex (p=0.173), platelet count (p=0.699), GGT (p=0.366), or FIB-4 score (p=0.967), while age showed a borderline trend (p=0.073). SIBO prevalence differed significantly across liver disease categories (p=0.0016), with the highest rate observed in active/acute HCV infection (64.3%), followed by other HCV-related disease (53.8%), whereas lower rates were found in MAFLD/NASH (31.3%), HBV (34.8%), cirrhosis (30.0%), and cured HCV (20.0%). In multivariable logistic regression, active/acute HCV emerged as a strong independent predictor of SIBO positivity (OR 7.20, 95% CI 2.92–17.74, p<0.001). Higher ALP also remained independently associated with SIBO (OR 1.04 per 10-unit increase, 95% CI 1.00–1.09, p=0.043), whereas age, sex, and ALT were not independently significant. The general distribution of patients is presented in Table 1.

Table 1. The general distribution of patients with liver diseases (SIBO(+) and SIBO(-)).

Disease Category
Total (n)
SIBO (+), n (%)
SIBO (−), n (%)
HCV active/acute
42
27 (64.3%)
15 (35.7%)
HCV (other)
13
7 (53.8%)
6 (46.2%)
HBV6623(34.8%)43(65.2%)
MAFLD/NASH
14445 (31.3%)
99 (68.7%)
Cirrhosis
103 (30.0%)
7 (70.0%)
HCV cured
306 (20.0%)
24 (80.0%)

Conclusion

SIBO is common in patients with liver diseases, affecting more than one-third of this cohort. SIBO positivity was associated with higher cholestatic and hepatocellular enzyme levels on univariate analysis, while active/acute HCV and elevated ALP remained independent predictors after adjustment. These findings support a clinically relevant interaction between intestinal dysbiosis and liver disease phenotype and suggest that patients with active HCV-related disease may represent a subgroup at particularly high risk for SIBO.

Conference

UEG Week Barcelona 2026

Topics

Hepatobiliary

Submission format

Abstract

Session

Gut–liver axis in liver disease: Microbiome, barrier dysfunction, and clinical consequences (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

Kaina Chen Kaina Chen, Jason Pik Eu Chang, David Chee Eng Ng, Brian Kim Poh Goh, David Tai, Apoorva Gogna, Chow Wei Too, Yiying Pei, Melvin Joel, Reagan Ng, Michael Chu

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

Esmira Abdullayeva Esmira Abdullayeva, Rashad Hasanov, Gülüstan Babayeva

Conclusion: Mistakes in… Upper GI

Conclusion: Mistakes in… Upper GI

Manuele Furnari Manuele Furnari

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

Dalila Gargouri Dalila Gargouri, Norsaf Bibani, Houssaina Jlassi, Dorra Trad, Sabbah Meriam, Sahar Hamza

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

Antonio Scafuri Antonio Scafuri, Alessandro Federico, Marcello Dallio, paola ciamarra, Fiammetta Di Nardo, Annachiara Coppola, Rossella D'Onofrio, Marina Cipullo, Mario Romeo, Paolo Vaia

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

Marten Lantinga Marten Lantinga, Robert Bart Takkenberg, Raoel Maan, Matthijs Kramer, Frans Cuperus, Minneke J. Coenraad, Gwen M.C. Masclee, Koos de Wit

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Conclusion: Mistakes in… Upper GI

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Conclusion: Mistakes in… Upper GI

Manuele Furnari 1

Affiliations

1 University of Genoa., Genoa, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

UEG Week Barcelona 2026

Topics

Small Intestine & Nutrition Surgery Neurogastroenterology & Motility

Session

Mistakes in… Upper GI

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

Kaina Chen Kaina Chen, Jason Pik Eu Chang, David Chee Eng Ng, Brian Kim Poh Goh, David Tai, Apoorva Gogna, Chow Wei Too, Yiying Pei, Melvin Joel, Reagan Ng, Michael Chu

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

Esmira Abdullayeva Esmira Abdullayeva, Rashad Hasanov, Gülüstan Babayeva

Conclusion: Mistakes in… Upper GI

Conclusion: Mistakes in… Upper GI

Manuele Furnari Manuele Furnari

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

Dalila Gargouri Dalila Gargouri, Norsaf Bibani, Houssaina Jlassi, Dorra Trad, Sabbah Meriam, Sahar Hamza

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

Antonio Scafuri Antonio Scafuri, Alessandro Federico, Marcello Dallio, paola ciamarra, Fiammetta Di Nardo, Annachiara Coppola, Rossella D'Onofrio, Marina Cipullo, Mario Romeo, Paolo Vaia

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

Marten Lantinga Marten Lantinga, Robert Bart Takkenberg, Raoel Maan, Matthijs Kramer, Frans Cuperus, Minneke J. Coenraad, Gwen M.C. Masclee, Koos de Wit

UEG Poster
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

Sahar Hamza 1, Sabbah Meriam 1, Dorra Trad 1, Houssaina Jlassi 1, Norsaf Bibani 1, Dalila Gargouri 1

Affiliations

1 Habib Thameur Hospital, Tunis, Tunisia

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Clinical Case Summary

We report the case of a 64-year-old man with preexisting hepatic sarcoidosis complicated by liver cirrhosis, who presented with confusion as an initial manifestation of COVID-19 confirmed by rapid Antigenic test. His Child Pugh score was 8 (Class B) and MELD was 16. Chest radiographs showed bilateral patchy interstitial opacities. Computed tomography (CT) of the brain was normal. Lumbar puncture was not performed because of a marked thrombocytopenia. Urine cytobacteriological examination did not show a urinary tract infection. An abdominal ultrasound showed normal hepatoportal flow and a mild ascites. Ascitic fluid analysis did not show spontaneous bacterial peritonitis. Since the patient was cirrhotic, we have considered the diagnosis of hepatic encephalopathy as a possible explanation for the neurological symptoms, so he started Lactulose and Rifaximin. However, his clinical condition showed no improvement, the neurological disorders remained the same. A brain MRI showed in FLAIR MR sequences a few hyperintensities punctiform in the white matter of the supratentorial region and the subcortical of the left insula region. There were no signs of a cerebral granuloma nor toxoplasmosis. It did not show venous thrombosis. There were no microheamorragies neither ischemic lesions. After careful evaluation by neurologic experts, encephalitis associated with SARS-CoV-2 infection was concluded. The patient was treated by intravenous Dexamethasone and he fully recovered without sequelae. This case illustrates the fact that neurological manifestations associated with COVID-19 infection are not necessarily a reflection of critical illness, and should incite clinicians to actively look for any evidence of COVID-19 infection as a differential diagnosis in patients with preexisting cirrhosis, presenting with neurological symptoms, during the epidemic period of COVID-19.

Conference

UEG Week Copenhagen 2023

Submission format

Clinical Case

Session

PP 12 Clinical Cases (Posters)

Published

2023

More Like This:

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

Kaina Chen Kaina Chen, Jason Pik Eu Chang, David Chee Eng Ng, Brian Kim Poh Goh, David Tai, Apoorva Gogna, Chow Wei Too, Yiying Pei, Melvin Joel, Reagan Ng, Michael Chu

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

Esmira Abdullayeva Esmira Abdullayeva, Rashad Hasanov, Gülüstan Babayeva

Conclusion: Mistakes in… Upper GI

Conclusion: Mistakes in… Upper GI

Manuele Furnari Manuele Furnari

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

Dalila Gargouri Dalila Gargouri, Norsaf Bibani, Houssaina Jlassi, Dorra Trad, Sabbah Meriam, Sahar Hamza

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

Antonio Scafuri Antonio Scafuri, Alessandro Federico, Marcello Dallio, paola ciamarra, Fiammetta Di Nardo, Annachiara Coppola, Rossella D'Onofrio, Marina Cipullo, Mario Romeo, Paolo Vaia

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

Marten Lantinga Marten Lantinga, Robert Bart Takkenberg, Raoel Maan, Matthijs Kramer, Frans Cuperus, Minneke J. Coenraad, Gwen M.C. Masclee, Koos de Wit

UEG Poster
Audio / Video Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

Paolo Vaia 1, Mario Romeo 1, Marina Cipullo 1, Rossella D'Onofrio 1, Annachiara Coppola 1, Fiammetta Di Nardo 1, Antonio Scafuri 1, paola ciamarra 1, Marcello Dallio 1, Alessandro Federico 1

Affiliations

1 University of Campania "Luigi Vanvitelli", Naples, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Clinical Case Summary

Background: Dysphagia represents a relatively common entity determined by a heterogeneous spectrum of frequent conditions ranging predominantly from oesophageal organic lesions (benign or malignant) to motility dysfunctions. However, rare extra-oesophageal causes of dysphagia, including neuromuscular disorders or mediastinum disorders, have been described.
Case presentation: A 61-year-old male patient was admitted to our department complaining of progressive worsening oropharyngeal dysphagia, especially for solid food. Six months before, he received an upper gastrointestinal barium X-ray showing no specific signs.
On admission, the diagnostic work-up included esophagogastroduodenoscopy (EGDS) and manometry: EGDS highlighted a hypopharyngeal sub-stenosis requiring the use of a paediatric endoscope to pass through it, while manometry evidenced an unspecific triple pressure trace at the upper oesophageal sphincter level suggesting an ab extrinsic compression. Moreover, an expert multidisciplinary “dysphagia” team composed of gastroenterologists, endocrinologists, otolaryngologists, and neurologists, excluded thyroid-related determinants, and ruled out other common causes of dysphagia.
Considering these findings, a neck-column CT scan was performed and the following radiological criteria of Diffuse Idiopathic Skeletal Hyperostosis (DISH) or “Forestier Syndrome” were revealed: flowing ossifications mainly along the anterior longitudinal ligament of at least four contiguous vertebrae with preserved inter-articular discs height and absence of apophyseal joints. Finally, the patient was surgically managed gaining the complete resolution of his symptoms.
Conclusion: DISH represents a rare cause of dysphagia. Clinicians should be aware that the diagnostic work-up of “unexplained” dysphagia should routinely include extra-oesophageal conditions, especially the rare ones.

References

  1. Mazières B. Diffuse idiopathic skeletal hyperostosis (Forestier-Rotes-Querol disease): what's new? Joint Bone Spine. 2013 Oct;80(5):466-70. doi: 10.1016/j.jbspin.2013.02.011. Epub 2013 Apr 6. PMID: 23566663.
  2. Karaarslan N, Gürbüz MS, Çalışkan T, Simsek AT. Forestier syndrome presenting with dysphagia: case report of a rare presentation. J Spine Surg. 2017 Dec;3(4):723-726. doi: 10.21037/jss.2017.11.05. PMID: 29354755; PMCID: PMC5760404
  3. Legaye J. Forestier's syndrome : a rare cause of dysphagia. A case report and review of the literature. Acta Orthop Belg. 2020 Jun;86(2):216-219. PMID: 33418609.

Conference

UEG Week Vienna 2024

Topics

Oesophagus

Submission format

Clinical Case

Session

Clinical Cases (Posters)

Published

2024

More Like This:

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

Kaina Chen Kaina Chen, Jason Pik Eu Chang, David Chee Eng Ng, Brian Kim Poh Goh, David Tai, Apoorva Gogna, Chow Wei Too, Yiying Pei, Melvin Joel, Reagan Ng, Michael Chu

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

Esmira Abdullayeva Esmira Abdullayeva, Rashad Hasanov, Gülüstan Babayeva

Conclusion: Mistakes in… Upper GI

Conclusion: Mistakes in… Upper GI

Manuele Furnari Manuele Furnari

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

Dalila Gargouri Dalila Gargouri, Norsaf Bibani, Houssaina Jlassi, Dorra Trad, Sabbah Meriam, Sahar Hamza

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

Antonio Scafuri Antonio Scafuri, Alessandro Federico, Marcello Dallio, paola ciamarra, Fiammetta Di Nardo, Annachiara Coppola, Rossella D'Onofrio, Marina Cipullo, Mario Romeo, Paolo Vaia

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

Marten Lantinga Marten Lantinga, Robert Bart Takkenberg, Raoel Maan, Matthijs Kramer, Frans Cuperus, Minneke J. Coenraad, Gwen M.C. Masclee, Koos de Wit

UEG Poster
Audio / Video Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

Koos de Wit 1, Gwen M.C. Masclee 1, Minneke J. Coenraad 2, Frans Cuperus 3, Matthijs Kramer 4, Raoel Maan 5, Robert Bart Takkenberg 1, Marten Lantinga 1

Affiliations

1 Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, Netherlands

2 Leiden University Medical Centre, Leiden, Netherlands

3 University Medical Center Groningen, Groningen, Netherlands

4 Maastricht University Medical Centre+, Maastricht, Netherlands

5 Erasmus University Medical Center, Rotterdam, Netherlands

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Chronic liver injury ultimately progresses to the development of cirrhosis. Patients with cirrhosis can be in a compensated or decompensated phase, the latter marked by clinical events such as ascites, hepatic encephalopathy and variceal bleeding. These events are associated with significant morbidity and mortality and the management is challenging and labor-intensive. Due to ongoing unhealthy lifestyle factors resulting in chronic liver injury, the burden of cirrhosis on healthcare systems in Europe is increasing. There is however limited data on the impact of cirrhosis on Dutch healthcare resources.

Aims & Methods

We aimed to determine the point-prevalence and claimed health costs of adults (≥ 18 years) registered as patients with cirrhosis at Dutch hospitals. To this end we extracted health claims data (timeframe 2017-2021) from the records of the Dutch health claims database (Vektis), which covers almost all inhabitants of the Netherlands. We used diagnosis codes ‘compensated cirrhosis’ and ‘decompensated cirrhosis’ to identify patients.

Results

The point prevalence of patients with cirrhosis increased from 48,7 patients per 100.000 adult Dutch inhabitants in 2017 to 75,2 per 100.000 in 2021 (+54%). The point-prevalence for cirrhosis was highest in the province of Limburg with 105,6 patients per 100.000 adult Dutch inhabitants. The annual increase in unique new patients for which hospitals claimed costs was n=3.725 in 2018, n=3.840 in 2019 (+3%), n=3.749 in 2020 (-2%) and n=3.695 in 2021 (-1%). The largest increase was observed in the province of Zuid-Holland (approximately 5 new patients per 100.000 adult Dutch inhabitants per year). Total number of hospital admissions increased with 19% from 2.443 admissions in 2017 to 2.899 admissions in 2021. The median length of stay for admitted patients with cirrhosis in 2017-2021 was four days [IQR 2-7 days]. The annual reported costs for patients with cirrhosis increased from €35 million in 2017 to €78 million in 2021 (+120%).

Conclusion

The point-prevalence of Dutch adults registered as a patient with cirrhosis in Dutch hospitals increased by more than fifty percent, with remarkable regional differences. Consequently, the total healthcare costs claimed for these patients more than doubled in less than five years.

Conference

UEG Week Copenhagen 2023

Topics

Hepatobiliary

Submission format

Abstract

Session

PP 07 Liver & biliary (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

ALBI AND AFP FOR RISK STRATIFICATION IN MULTIDISCIPLINARY TUMOUR BOARD–MANAGED HEPATOCELLULAR CARCINOMA: A REAL-WORLD SINGAPORE COHORT

Kaina Chen Kaina Chen, Jason Pik Eu Chang, David Chee Eng Ng, Brian Kim Poh Goh, David Tai, Apoorva Gogna, Chow Wei Too, Yiying Pei, Melvin Joel, Reagan Ng, Michael Chu

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

PREVALENCE AND INDEPENDENT PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH LIVER DISEASES: A CROSS-SECTIONAL STUDY

Esmira Abdullayeva Esmira Abdullayeva, Rashad Hasanov, Gülüstan Babayeva

Conclusion: Mistakes in… Upper GI

Conclusion: Mistakes in… Upper GI

Manuele Furnari Manuele Furnari

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

COVID-19 ENCEPHALITIS IN A CIRRHOTIC PATIENT

Dalila Gargouri Dalila Gargouri, Norsaf Bibani, Houssaina Jlassi, Dorra Trad, Sabbah Meriam, Sahar Hamza

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

A RARE AND UNEXPECTED CAUSE OF DYSPHAGIA IN A 61-YEAR-OLD MALE: DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) (“FORESTIER SYNDROME”)

Antonio Scafuri Antonio Scafuri, Alessandro Federico, Marcello Dallio, paola ciamarra, Fiammetta Di Nardo, Annachiara Coppola, Rossella D'Onofrio, Marina Cipullo, Mario Romeo, Paolo Vaia

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

INCREASE IN POINT-PREVALENCE AND COSTS OF LIVER CIRRHOSIS IN THE NETHERLANDS – A NATIONWIDE HEALTH CLAIMS DATA ANALYSIS

Marten Lantinga Marten Lantinga, Robert Bart Takkenberg, Raoel Maan, Matthijs Kramer, Frans Cuperus, Minneke J. Coenraad, Gwen M.C. Masclee, Koos de Wit

The global reference point for the digestive health community

Platform Publisher

United European Gastroenterology

Wickenburggasse 1 1080 Vienna, Austria

Contact us

support@ueg.eu

ueg.eu

T: +43 1 997 1639

Legal

Terms & Conditions

Imprint

Privacy Policy

Explore

My Bookmarks

My recommendations

My fields of interest

© 2026 United European Gastroenterology

Change fields of interest

These fields are selected based on the interests in your myUEG profile.
Click the item to unselect it. You can select multiple items.